Effectiveness of continuous femoral nerve block for pain relief after total knee arthroplasty: comparison with epidural patient-controlled analgesia and periarticular injection

Myung Ku Kim, Sang Hyun Ko, Yoon Joong Hwang, Dae Gyu Kwon, Yoon Sang Jeon and Dong Jin Ryu

Abstract
Objective: To compare the clinical outcomes among three analgesic techniques, continuous femoral nerve block (CFNB), epidural patient-controlled analgesia (EPCA) and periarticular injection (PAI), in patients undergoing total knee arthroplasty (TKA).

Methods: This retrospective case–control study enrolled patients that underwent TKA. Visual analogue scale (VAS) pain scores, sleep disturbance, additional opioid consumption and incidence of opioid-related side-effects were assessed.

Results: A total of 120 patients were categorized into three groups: EPCA (group A, n = 40), PAI (group B, n = 40) and CFNB (group C, n = 40). Group C had significantly lower VAS pain scores than groups A and B at 8, 12 and 24 h after TKA. There were no significant differences in VAS pain scores among the three groups from 48 h after TKA. Sleep quality on the first day after surgery was significantly better in group C than in groups A and B. Additional opioid consumption was significantly lower in the group C than in the groups A and B. Group C showed a lower rate of opioid-related side-effects than groups A and B.

Conclusion: CFNB was a more effective additional analgesic technique than EPCA or PAI for acute postoperative pain control within 24 h of TKA.

Corresponding author:
Dong Jin Ryu, Department of Orthopaedic Surgery, Inha University Hospital, 27 Inhang-ro, Jung-gu, Incheon, 22332, Republic of Korea.
Email: mdryu24@naver.com
Keywords
Knee, total knee arthroplasty, postoperative pain management, femoral nerve block, periarticular injection, patient-controlled analgesia, opioid

Date received: 1 November 2021; accepted: 14 February 2022

Introduction

Pain management after total knee arthroplasty (TKA) is a significant issue because many patients experience intolerable pain.1–5 Severe pain experienced during the early postoperative period impedes early rehabilitation by hampering the patient’s ability to perform activities and may increase the risk of postoperative complications, including thromboembolic disease or nosocomial infections.1,2,5 Several techniques such as epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) and femoral nerve block (FNB) have been developed and widely used to control initial pain after TKA.2–4,6 These techniques allow for early ambulation and physiotherapy initiation, which in turn expedite recovery, reduce length of hospital stay and lower postoperative complication risk.1,2

Intravenous patient-controlled analgesia (IV-PCA) is used for effective pain relief. However, some patients experience several side-effects of opioid drugs, including nausea, vomiting, headache, dizziness and urinary retention.3,6 EPCA is widely used to manage postoperative pain because it has fewer side-effects than IV-PCA.7,8 Recently, interest in localized additional pain management methods, including FNB and PAI, has been increasing owing to their ability to ameliorate pain with few adverse effects.1,6 FNB is an effective technique, but it can damage quadricep muscle power, which in turn delays ambulation and recovery.1,2 EPCA is an invasive procedure that restricts the mobility of patients until they completely recover motor power. PAI has several advantages including simplicity of the technique and avoidance of motor blockade, but its analgesic efficacy is limited owing to its short duration of action.5

In terms of comparing EPCA, PAI and FNB, most studies have only included two of the techniques.3,6 To the best of our knowledge, no study has identified which of the three techniques is the most effective. The aim of this current study was to evaluate the effectiveness of pain management of the three techniques as well as their side-effects in patients undergoing primary TKA.

Patients and methods

Study population

This retrospective matched-pair case–control study enrolled consecutive patients that underwent primary TKA and received continuous femoral nerve block (CFNB) and the same number of consecutive patients that underwent primary TKA with EPCA and PAI according to the matching criteria between January 2014 and December 2019 in the Department of Orthopaedic Surgery, Inha University Hospital, Incheon, Republic of Korea. The patients were matched by age (±5 years), sex, cause of TKA (primary osteoarthritis), body mass index (BMI; ±2 kg/m²), Kellgren and Lawrence stage, pre-operative pain score (±1 visual analogue scale [VAS]) and tourniquet time (±10 min). All of the patients underwent surgery by the same surgeon (M.K.K.). Patients were categorized into three groups: group A
(EPCA), group B (PAI) and group C (CFNB).

The inclusion criteria were as follows: (i) received unilateral surgery; (ii) surgery undertaken by a single surgeon (M.K.K.). The exclusion criteria were as follows: (i) receipt of IV-PCA; (ii) receipt of simultaneous bilateral TKA; (iii) receipt of another surgery at the same time; (iv) contraindication to spinal anaesthesia (general anaesthesia); (v) allergy to local anaesthesia; (vi) local site infection; (vii) previous nerve injury; (viii) peripheral neuropathy; (ix) neuropathic pain; (x) history of stroke or major neurological deficit; (xi) psychiatric illness; (xii) abnormal liver, renal or cardiac function; (xiii) chronic kidney disease requiring dialysis; (xiv) morbid obesity (BMI >40 kg/m²); (xv) chronic use of opioids; (xvi) previous drug dependency; (xvii) inability to walk independently; (xviii) uncooperative patients.

The design and protocol of this study were reviewed and approved by the institutional review board of Inha University Hospital, Incheon, Republic of Korea (IRB no. INHAUH 2020-05-001) and an exemption from informed consent was obtained. The reporting of this study conformed to STROBE guidelines.9

**Surgical procedures**

All patients underwent TKA performed by the same surgeon (M.K.K.) and were subjected to the same procedures and postoperative management techniques. Under spinal anaesthesia, the patient was placed in the supine position, after applying a pneumatic tourniquet with the same pressure (350 mmHg). A standard mid-line skin incision was made with medial parapatellar approach. The same implant system (NexGen LPS® PS type; Zimmer Biomet, Warsaw, IN, USA) was adjusted with cement fixation (Optipac 80; Biomet Orthopaedics GmbH, Dietikon, Switzerland) in all patients. Pain management and early postoperative rehabilitation protocols were similarly applied in all patients.

**Premedication and spinal anaesthesia**

Premedication was given to patients with a small volume of water as they departed for the operating room: (i) 37.5 mg tramadol hydrochloride/325 mg acetaminophen (Ultracet® tablet; Janssen Korea, Seoul, Republic of Korea); (ii) 2 mg polmacoxib (Acelex® tablet; CrystalGenomics, Seoul, Republic of Korea); (iii) 300 mg gabapentin (Neurontin® capsule; Jeil Pharm., Seoul, Republic of Korea). Standard monitoring (pulse oximeter, electrocardiography and non-invasive arterial pressure) was performed on all patients on their arrival to the anaesthetic room. After an intravenous (i.v.) preload with 500 ml of plasma solution, spinal anaesthesia was administered in the lateral position by inserting either a 25G or 27G spinal needle into the L2–L3 or L3–L4 intervertebral space. After confirming clear free flow of cerebrospinal fluid, 12.5 mg of racemic 0.5% bupivacaine was administered to achieve sensory block (to cold and pinprick) to the 10th thoracic dermatome or above.

**Additional pain control procedure**

For EPCA, after spinal anaesthesia, an epidural catheter was inserted approximately 4 cm in the direction of the head and then the patient was placed in the supine position. In the recovery room, when the sensory block height fell below T10, the patient received a continuous dose of total 100 ml of 0.75% ropivacaine 20 ml and 5 mg of 0.1% morphine sulphate with normal saline, after the administration of a 3-ml bolus dose of 0.1% ropivacaine with 1 ml 0.1% morphine sulphate via an epidural catheter as an initial loading dose.
An epidural pain control device was administered for 72 h at a rate of 2 ml/h.

For CFNB, the femoral nerve block was administered to the patient in the supine position. The pulse of the femoral artery was identified. Under ultrasonographic guidance, an 18G echogenic needle with stimulating catheter (E-Cath® Plus; Pajunk GmbH Medizintechnologie, Geisingen, Germany) was introduced 1 cm lateral to the femoral artery at the inguinal skin crease and advanced toward the cephalad at an angle of 45°–60° to the skin. Correct identification of the nerve was confirmed by the contraction of the quadriceps muscle using a nerve stimulator set between 0.2 and 0.5 mA (0.1 ms, 1 Hz). When appropriate muscle contractions were obtained between 0.2 mA and 0.5 mA, 25 ml of a local anaesthetic mixture containing 0.75% ropivacaine (5 ml) mixed with normal saline (20 ml) was slowly injected via a needle for each block after negative aspiration of blood. The catheter was then threaded with caution to maintain at all times the desired motor response. The threshold accepted for final catheter positioning was 0.8 mA of current intensity (0.1 ms width, 2 Hz). The catheter was then tunnelled for 5–7 cm under the skin to minimize dislodgement. This was followed by a continuous infusion of 0.75% ropivacaine 60 ml mixed with normal saline 140 ml (0.225% ropivacaine, total 200 ml) at a rate of 3 ml/h. The catheter was maintained during 72 h and then removed.

For the PAI, an injection solution containing a total volume of 100 ml of 0.2% ropivacaine, 1 ml of ketorolac (30 mg/ml) and 0.5 ml of epinephrine (1 mg/ml). This solution was injected into the rest of the capsule, the cut quadriceps tendon, the patellar ligament and soft tissues surrounding the joint, and the subcutaneous tissues after suturing the incision made during medial parapatellar arthroscopy.

**Clinical assessment**

For each group, four clinical assessments were compared for evaluating the effects. The effect of each technique on postoperative pain relief was estimated at rest and after 4, 8, 12, 24, 48 and 72 h using a VAS score (0–10 cm, where 0 indicates no pain and 10 indicates extreme pain).

The quality of sleep subjectively experienced by the patients on the first day after surgery was investigated using a questionnaire (Table 1). The patients were surveyed on the day after surgery. The score ranged from 0 to 10, where 0 point indicated no sleep disturbance; 1–3 points, mild sleep disturbance; 4–6 points, moderate sleep disturbance; and 7–10 points, severe sleep disturbance.

Consumption of additional opioids in each group was checked and calculated by converting to a corresponding dose of morphine as described below. The incidence of opioid side-effects, such as nausea/vomiting, dizziness, headache, constipation and sedation, was recorded for the first 72 h after surgery.

**Consumption of additional opioids**

To supplement the three analgesic regimens, 50 mg/ml tramadol hydrochloride (Tridol injection 50 mg; Yuhan, Seoul, Republic of Korea) i.v. was used for controlling pain when pain at rest exceeded 5 on the VAS. A pethidine hydrochloride (25 mg/0.5 ml; Hana Pethidine HCL Injection 25 mg; Hana Pharm Co., Seoul, Republic of Korea) i.v. injection was used for treating severe pain (>7 on the VAS). Consumption of additional opioids was converted to an equivalent dose of oral morphine using the guidelines published by the National Drug and Alcohol Research Center.
Statistical analyses

All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp., Armonk, NY, USA). Continuous data are presented as mean ± SD and categorical data as n of patients (%). A repeated measures analysis of variance (ANOVA) test was undertaken to analyse the change in VAS pain score over different time-points. Continuous data were analysed using a one-way ANOVA test and categorical data were analysed using Pearson’s χ²-test. A Scheffe’s post-hoc test was used to assess any statistical significance between the time-points and between the groups at a defined time. A P-value <0.05 was considered statistically significant.

Results

The patient selection and matching process is presented in Figure 1. Of 564 patients that underwent TKA, 374 patients were included in the study after applying the exclusion criteria. Of the 374 patients, 40 patients underwent CFNB (group C); and 40 patients that underwent EPCA (group A) or PAI (group B) were selected according to the matching criteria. Age, sex, surgical side, BMI and tourniquet time of the patients before surgery are presented in Table 2. Among the three groups, there were no significant differences in these variables.

The mean VAS pain scores of the three groups at 4, 8, 12, 24, 48 and 72 h after TKA are presented in Table 3. Among the three groups overall, significant differences in the mean VAS pain scores were observed at 8, 12 and 24 h (P < 0.001 for all comparisons), whereas there were no significant differences at 4, 48 and 72 h. Group C (CFNB) had significantly better pain scores than groups A (EPCA) and B.

Table 1. A questionnaire for evaluating sleep quality on the first day after surgery in a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia, periarticular injection or continuous femoral nerve block in patients that underwent total knee arthroplasty.

| Questions                                                                 | Score |
|---------------------------------------------------------------------------|-------|
| Did you sleep well on the first night after the surgery compared with usual? |       |
| Very well                                                                 | 0     |
| Well                                                                      | 1     |
| Not really                                                                | 2     |
| No                                                                        | 3     |
| Have the analgesics helped you sleep well?                                |       |
| Very effective                                                            | 0     |
| Effective                                                                 | 1     |
| Little effective                                                          | 2     |
| Ineffective                                                               | 3     |
| How many additional analgesics did you take to fall asleep?               |       |
| Three +                                                                   | 4     |
| Three                                                                     | 3     |
| Two                                                                       | 2     |
| One                                                                       | 1     |
| None                                                                      | 0     |
| Total score<sup>a</sup>                                                   | 10    |

<sup>a</sup>0 point, no sleep disturbance; 1–3 points, mild sleep disturbance; 4–6 points, moderate sleep disturbance; 7–10 points, severe sleep disturbance.
PAI at 8, 12 and 24 h ($P < 0.001$ for all comparisons). Group B (PAI) had a better mean VAS pain score than group A (EPCA) at 8 h ($P = 0.016$) and 12 h ($P = 0.047$), but both groups had similar pain scores at other times.

The sleep quality scores showed that 11 of 40 patients (27.5%) in group A (EPCA), 13 of 40 patients (32.5%) in group B (PAI) and 22 of 40 patients (55.0%) in group C (CFNB) had no sleep disturbance (Table 4). Sleep quality during the first postoperative night was significantly better in group C (CFNB) than in groups A (EPCA) and B (PAI) ($P = 0.028$). A total of 33 of 40 patients (82.5%) in group C (CFNB) reported a sleep disturbance of either ‘none’ or ‘mild’ grade. There were no significant differences between groups A (EPCA) and B (PAI) in terms of sleep disturbance.

The additional analgesic requirements are presented in Figure 2. The cumulative mean ± SD opioid consumption (converted to an equivalent dose of oral morphine) at 72 h was as follows: 67.4 ± 19.2 mg in group A (EPCA), 62.9 ± 14.3 mg in group B (PAI) and 33.4 ± 17.5 mg in group C (CFNB). The cumulative opioid consumption was significantly lower in the group C (CFNB) compared with groups A (EPCA) and B (PAI) ($P < 0.001$ for both comparisons). There were no significant differences between groups A (EPCA) and B (PAI). In each group, opioid consumption between 24 h and 48 h (24 h < t ≤ 48 h) was significantly

---

**Figure 1.** Flowchart of patient selection for a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) or continuous femoral nerve block (CFNB) in patients that underwent total knee arthroplasty (TKA). OA, osteoarthritis; IV-PCA, intravenous-patient-controlled analgesia; BMI, body mass index; VAS, visual analogue scale.
higher than that between 0 and 24 h 
\((t/C_{20}^{24 \text{ h}})\) or between 48 and 72 h \((48 \text{ h} < t/C_{20}^{72 \text{ h}})\) \((P < 0.001 \text{ for all comparisons}).

Groups A (EPCA), B (PAI) and C (CFNB) had 14 of 40 patients (35.0%), 12 of 40 patients (30.0%) and eight of 40 patients (20.0%) with probable side-effects of opioid use, respectively. There were no significant differences among the three groups. The most frequent side-effects in all patients were postoperative nausea and vomiting (PONV) (15 of 34 patients; 44.1%), dizziness/headache (nine of 34 patients; 26.5%), constipation

### Table 2. Preoperative demographic and clinical characteristics of patients \((n = 120)\) included in a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) or continuous femoral nerve block (CFNB) following total knee arthroplasty.

| Characteristics                  | Group          |
|----------------------------------|----------------|
|                                  | EPCA \(n = 40\) | PAI \(n = 40\) | CFNB \(n = 40\) |
| Age, years                       | 70.8 ± 7.8     | 69.4 ± 6.5     | 70.9 ± 5.3     |
| Sex                              |                |                |                |
| Female                           | 30 (75.0%)     | 30 (75.0%)     | 30 (75.0%)     |
| Male                             | 10 (25.0%)     | 10 (25.0%)     | 10 (25.0%)     |
| Side                             |                |                |                |
| Right                            | 22 (55.0%)     | 25 (62.5%)     | 23 (57.5%)     |
| Left                             | 18 (45.0%)     | 15 (37.5%)     | 17 (42.5%)     |
| Body mass index, kg/m\(^2\)      | 26.7 ± 3.8     | 26.4 ± 2.8     | 26.6 ± 3.3     |
| Tourniquet time, min             | 92.3 ± 9.5     | 93.7 ± 8.1     | 95.0 ± 9.5     |

Data presented as mean ± SD or \(n\) of patients (%).
No significant between-group differences \((P ≥ 0.05);\) continuous data were compared using one-way analysis of variance; categorical data were compared using Pearson’s \(\chi^2\)-test.

### Table 3. Visual analogue scale (VAS) pain scores during the 72 h after total knee arthroplasty in patients \((n = 120)\) included in a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) or continuous femoral nerve block (CFNB).

| Postoperative time-point | EPCA \(n = 40\) | PAI \(n = 40\) | CFNB \(n = 40\) | Statistical analyses\(^{a}\) |
|--------------------------|-----------------|----------------|-----------------|-----------------------------|
|                          | Overall         | EPCA versus   | EPCA versus   | PAI versus     |
|                          | significance    | PAI            | CFNB            | CFNB            |
| 4 h                      | 2.57 ± 1.36     | 2.29 ± 0.46    | 2.11 ± 0.51    | NS             | NS              | NS              | NS              |
| 8 h                      | 4.86 ± 1.70     | 3.94 ± 1.08    | 2.29 ± 0.89    | \(P < 0.001\)   | \(P = 0.016\)   | \(P < 0.001\)   | \(P < 0.001\)   |
| 12 h                     | 6.86 ± 2.22     | 5.83 ± 1.58    | 2.91 ± 1.07    | \(P < 0.001\)   | \(P = 0.047\)   | \(P < 0.001\)   | \(P < 0.001\)   |
| 24 h                     | 5.09 ± 1.42     | 4.97 ± 1.15    | 3.09 ± 0.98    | \(P < 0.001\)   | NS              | \(P < 0.001\)   | \(P < 0.001\)   |
| 48 h                     | 3.60 ± 1.09     | 3.71 ± 1.02    | 3.46 ± 1.12    | NS              | NS              | NS              | NS              |
| 72 h                     | 2.91 ± 1.12     | 3.26 ± 0.89    | 3.11 ± 0.83    | NS              | NS              | NS              | NS              |

Data presented as mean ± SD.
\(^{a}\)Continuous data were compared using one-way analysis of variance followed by Scheffe’s post-hoc analysis; NS, no significant difference \((P ≥ 0.05).\)
Table 4. Adverse events and sleep disturbance after total knee arthroplasty in patients (n = 120) included in a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) or continuous femoral nerve block (CFNB).

| Group | EPCA n = 40 | PAI n = 40 | CFNB n = 40 |
|-------|-------------|------------|-------------|
| Adverse events | | | |
| Overall | 14 (35.0%) | 12 (30.0%) | 8 (20.0%) |
| Nausea/vomiting | 7 (50.0%) | 5 (41.7%) | 3 (37.5%) |
| Dizziness/headache | 4 (28.6%) | 3 (25.0%) | 2 (25.0%) |
| Constipation | 1 (7.1%) | 2 (16.7%) | 2 (25.0%) |
| Urinary retention | 2 (14.3%) | 2 (16.7%) | 1 (12.5%) |
| Sleep disturbancea | | | |
| None (0) | 11 (27.5%) | 13 (32.5%) | 22 (55.0%) |
| Mild (1–3) | 7 (17.5%) | 8 (20.0%) | 11 (27.5%) |
| Moderate (4–6) | 11 (27.5%) | 11 (27.5%) | 5 (12.5%) |
| Severe (7–10) | 11 (27.5%) | 8 (20.0%) | 2 (5.0%) |

Data presented as n of patients (%).

aP = 0.028 for sleep disturbance; Pearson’s χ²-test.

Figure 2. Consumption of opioids at 72 h after total knee arthroplasty for patients (n = 120) included in a study that investigated the effectiveness of pain management using epidural patient-controlled analgesia (EPCA), periarticular injection (PAI) or continuous femoral nerve block (CFNB). All opioids were converted to an equivalent dose of oral morphine (mg). Mean cumulative equivalent doses were compared using one-way analysis of variance. The colour version of this figure is available at: http://imr.sagepub.com.
(five of 34 patients; 14.7%) and urinary retention (five of 34 patients; 14.7%) (Table 4). There were no significant differences among patients in the three groups in terms of the adverse events that they experienced.

Discussion

The most important finding of this current study was that CFNB was associated with significantly lower pain scores compared with EPCA or PAI at 8, 12 and 24 h after TKA surgery. Moreover, CFNB could reduce additional opioid consumption at 72 h after TKA surgery and reduce the incidence of PONV.

Postoperative pain after TKA is a significant concern to patients and surgeons and appropriate pain management is essential for early mobilization and functional recovery.15,16 The conventional analgesia approaches after TKA include IV-PCA or EPCA.16 However, the use of systemic opioids is associated with side-effects such as nausea, vomiting, pruritus and sedation.7,17 These adverse effects may compromise early rehabilitation after TKA.1 The rationale for using an analgesic cocktail is that pharmaceutical synergy produces more effective analgesia.18,19 However, studies to determine the drug combinations that play the most important role in improving postoperative pain control are lacking.20 Many studies on PAI have revealed good results for various medications and combinations including ropivacaine, ketorolac and epinephrine.18–23 All of these combinations reportedly showed good efficacy toward pain control with only a few complications.20 This current study used a combination of ropivacaine, ketorolac and epinephrine. Epinephrine prolongs the action of local agents by facilitating contraction of the smooth muscles that line the arterioles to potentially minimize intra-articular bleeding and prolong the time the agents would act locally.24 The component ketorolac not only acts as an anti-inflammatory analgesic but also possesses synergistic activity when administered along with other oral nonsteroidal anti-inflammatory drugs.18 The current results demonstrated that the pain reduction mediated by PAI was significantly better than that mediated by EPCA at 8 h and 12 h after TKA surgery. However, the pain reduction brought about by PAI could not be prolonged beyond 12 h and was not superior to that mediated by CFNB.

Femoral nerve block has been introduced as an effective method for postoperative pain control after TKA.1,2,25,26 Several studies have demonstrated that the addition of FNB in TKA provides the patients with a higher quality of postoperative pain control and improves patient satisfaction with fewer side-effects during the early postoperative period.1,2,25–27 FNB can be applied as a single-shot FNB (SSFNB) or as a continuous block using a catheter and an infusion pump (CFNB). CFNB has the advantage of permitting analgesic delivery for a longer postoperative duration as opposed to SSFNb.26,27 Previous studies have shown that the duration of SSFNb-mediated analgesic effect is typically 12–24 h, whereas severe pain does not considerably fade for
48–72 h after TKA.\textsuperscript{27} CFNB has the advantage of permitting analgesic delivery for a longer postoperative duration than SSFNB.\textsuperscript{26} In consideration of this pain duration, the current study used CFNB and the results showed that compared with EPCA or PAI, the pain relief mediated by CFNB was significantly greater at 24 h after TKA; but after 48 h, the extent of pain relief was not significantly different between the three pain management methods.

Femoral nerve block has more efficient analgesic outcomes, although quadriceps femoris weakness following FNB is a significant concern.\textsuperscript{1,2,25,28,29} It is important because it can lead not only to delays in rehabilitation but also falls or fracture events.\textsuperscript{1,29} Although quadriceps muscle weakness after FNB is generally observed for approximately 3–6 months, several studies have demonstrated that there is no difference in clinical recovery.\textsuperscript{1,29} The power of the quadriceps femoris muscle was not measured in the current study, but there were no falls or fracture events with regard to motor block of the quadriceps muscle and no incidence of neurological dysfunctions that could not be treated by rehabilitation.

This study had several limitations. First, the study had an inherent limitation of not being a randomized, prospective study but rather a retrospective study. However, a matched-pair case–control study design was used for matching variables in order to improve the reliability of the results. Secondly, substantial variance in self-reported pain scores may routinely arise among patients despite imparting education on rating the pain score and having an understanding of the value of using aggregate scores. Thirdly, the concentrations and doses of ropivacaine in CFNB and EPCA were different and this could have affected the results. Because of differences in typical concentrations and doses between central anaesthesia and peripheral anaesthesia, it was not possible to match the exact drug concentrations between the two groups. Finally, the effect of CFNB or PAI may be technique-dependent, which could affect the clinical results. However, the injection regimen was identical and was performed by the same surgeon or anaesthesiologist, which minimized the potential for confounding effects on anaesthetic technique.

In conclusion, CFNB was a more effective additional analgesic technique than EPCA or PAI for achieving acute postoperative pain control within 24 h of TKA surgery. CFNB had a significant positive impact on sleep quality on the first day after surgery and reduced opioid consumption compared with EPCA or PAI.

**Author contributions**

Myung Ku Kim, Dong Jin Ryu, Dae Gyu Kwon and Yoon Sang Jeon designed the study. Sang Hyun Ko and Yoon Joong Hwang performed the data collection and participated in manuscript preparation. Sang Hyun Ko performed the statistical analysis. Myung Ku Kim performed the surgeries. All authors have read and approved the final manuscript.

**Declaration of conflicting interest**

The authors declare that there are no conflicts of interest.

**Funding**

The authors disclosed receipt of the following financial support for the research, authorship, and publication of this article: This study was supported by an Inha University research grant/Inha University Hospital research grant.

**ORCID iDs**

Sang Hyun Ko \textsuperscript{b} https://orcid.org/0000-0002-0368-6605

Dong Jin Ryu \textsuperscript{b} https://orcid.org/0000-0001-9371-2469
References

1. Paul JE, Arya A, Hurlburt L, et al. Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials. Anesthesiology 2010; 113: 1144–1162.

2. Kadric L, Boonstra MC, De Waal Malefijt MC, et al. Continuous femoral nerve block after total knee arthroplasty? Acta Anaesthesiol Scand 2009; 53: 914–920.

3. Toftdahl K, Nikolajsen L, Haraldsted V, et al. Comparison of peri- and intraarticular analgesia with femoral nerve block after total knee arthroplasty: a randomized clinical trial. Acta Orthop 2007; 78: 172–179.

4. Gandhi HJ, Trivedi LH, Tripathi DC, et al. A randomized, controlled trial of comparison of a continuous femoral nerve block (CFNB) and continuous epidural infusion (CEI) using 0.2% ropivacaine for postoperative analgesia and knee rehabilitation after total knee arthroplasty (TKA). J Anaesthesiol Clin Pharmacol 2019; 35: 386–389.

5. Marino J, Scuerdi G, Dowling O, et al. Periarticular knee injection with liposomal bupivacaine and continuous femoral nerve block for postoperative pain management after total knee arthroplasty: a randomized controlled trial. J Arthroplasty 2019; 34: 495–500.

6. Chandy VJ, Ajith K, Krishnamoorthy VP, et al. How effective is periarticular drug infiltration in providing pain relief following total knee replacement as compared to epidural analgesia? J Arthrosc Jt Surg 2019; 6: 103–107.

7. Seet E, Leong WL, Yeo ASN, et al. Effectiveness of 3-in-1 continuous femoral block of differing concentrations compared to patient controlled intravenous morphine for post total knee arthroplasty analgesia and knee rehabilitation. Anaesth Intensive Care 2006; 34: 25–30.

8. Rockemann MG, Seeling W, Goertz AW, et al. Effectiveness, side effects and costs of postoperative pain therapy: intravenous and epidural patient-controlled analgesia (PCA). Anaesthesiol Intensivmed Notfallmed Schmerzther 1997; 32: 414–419 [Article in German, English abstract].

9. von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147: 573–577.

10. Lee SH, Kim KH, Cheong SM, et al. A comparison of the effect of epidural patient-controlled analgesia with intravenous patient-controlled analgesia on pain control after posterior lumbar instrumented fusion. J Korean Neurosurg Soc 2011; 50: 205–208.

11. Yie JC, Yang JT, Wu CY, et al. Patient-controlled analgesia (PCA) following video-assisted thoracoscopic lobectomy: comparison of epidural PCA and intravenous PCA. Acta Anaesthesiol Taiwan 2012; 50: 92–95.

12. Carli F, Clemente A, Asenjo JF, et al. Analgesia and functional outcome after total knee arthroplasty: periarticular infiltration vs continuous femoral nerve block. Br J Anaesth 2010; 105: 185–195.

13. Magistris L, Casati A, Albertin A, et al. Combined sciatic-femoral nerve block with 0.75% ropivacaine: effects of adding a systemically inactive dose of fentanyl. Eur J Anaesthesiol 2000; 17: 348–353.

14. Nielsen S, Degenhardt L, Hoban B, et al. Comparing opioids: A guide to estimating oral morphine equivalents (OME) in research. Technical Report No. 329 Sydney: National Drug and Alcohol Research Centre, University of NSW, https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/TR.329.pdf (2014, accessed 23 February 2022).

15. Goyal N, McKenzie J, Sharkey PF, et al. Intra-articular infusion with bupivacaine decreased pain and opioid consumption after total knee arthroplasty. J Bone Joint Surg Am 2013; 95: 940.

16. Ekman EF and Koman AL. Acute pain following musculoskeletal injuries and orthopaedic surgery: mechanisms and management. Instr Course Lect 2005; 54: 21–33.

17. Lee RM, Tey JBL and Chua NHL. Postoperative pain control for total knee surgery.
arthroplasty: continuous femoral nerve block versus intravenous patient controlled analgesia. *Anesth Pain Med* 2012; 1: 239–242.

18. Sreedharan Nair V, Ganeshan Radhamony N, Rajendra R, et al. Effectiveness of intraoperative periarticular cocktail injection for pain control and knee motion recovery after total knee replacement. *Arthroplast Today* 2019; 5: 320–324.

19. Sadigursky D, Simões DP, de Albuquerque RA, et al. Local periarticular analgesia in total knee arthroplasty. *Acta Ortop Bras* 2017; 25: 81–84.

20. Yuenyongviwat V, Pornrattanananowanong C, Chinachoti T, et al. Periarticular injection with bupivacaine for postoperative pain control in total knee replacement: a prospective randomized double-blind controlled trial. *Adv Orthop* 2012; 2012: 107309.

21. Busch CA, Shore BJ, Bhandari R, et al. Efficacy of periarticular multimodal drug injection in total knee arthroplasty. A randomized trial. *J Bone Joint Surg Am* 2006; 88: 959–963.

22. Ranawat AS and Ranawat CS. Pain management and accelerated rehabilitation for total hip and total knee arthroplasty. *J Arthroplasty* 2007; 22: 12–15.

23. Parvataneni HK, Shah VP, Howard H, et al. Controlling pain after total hip and knee arthroplasty using a multimodal protocol with local periarticular injections: a prospective, randomized study. *J Arthroplasty* 2007; 22: 33–38.

24. Kelley TC, Adams MJ, Mulliken BD, et al. Efficacy of multimodal perioperative analgesia protocol with periarticular medication injection in total knee arthroplasty: a randomized, double-blinded study. *J Arthroplasty* 2013; 28: 1274–1277.

25. Borys M, Domagała M, Wencław K, et al. Continuous femoral nerve block is more effective than continuous adductor canal block for treating pain after total knee arthroplasty: a randomized, double-blind, controlled trial. *Medicine (Baltimore)* 2019; 98: e17358.

26. Chan EY, Fransen M, Parker DA, et al. Femoral nerve blocks for acute postoperative pain after knee replacement surgery. *Cochrane Database Syst Rev* 2014: CD009941.

27. de Lima E Souza R, Correa CH, Henriques MD, et al. Single-injection femoral nerve block with 0.25% ropivacaine or 0.25% bupivacaine for postoperative analgesia after total knee replacement or anterior cruciate ligament reconstruction. *J Clin Anesth* 2008; 20: 521–527.

28. Bauer M, Wang L, Onibonoje OK, et al. Continuous femoral nerve blocks: decreasing local anesthetic concentration to minimize quadriceps femoris weakness. *Anesthesiology* 2012; 116: 665–672.

29. Runner RP, Boden SA, Godfrey WS, et al. Quadriceps strength deficits after a femoral nerve block versus adductor canal block for anterior cruciate ligament reconstruction: a prospective, single-blinded, randomized trial. *Orthop J Sports Med* 2018; 6: 2325967118797990.